Pfizer hoping to win over analysts at upcoming R&D day

Share this article:
Pfizer is slated to deliver a detailed pipeline update Thursday, as it tries to boost investor confidence in its roster of experimental compounds. The six-hour meeting will be Web cast live and is set to be hosted by new chief executive Jeffrey Kindler. He’ll have an audience of analysts ready to hear his plan for replacing erstwhile top earners such as antibiotic Zithromax and antidepressant Zoloft. Cholesterol drug Lipitor, with $12 billion in annual sales, is set to lose patent protection in 2010. Pfizer is expected to present the latest data on Lipitor’s possible successor, torcetrapib, which in large-scale clinical testing has been shown to boost good cholesterol but raise blood pressure. Earlier this month, the American Heart Association prevented Pfizer from presenting data on the closely watched developmental drug at its annual meeting after AHA officials said Pfizer broke the organization’s rules of discussing results ahead of their presentation. Pfizer said today it ended a research collaboration with Akzo's Organon unit to develop asenapine, a treatment for schizophrenia and bipolar disorder which analysts had predicted could become a blockbuster. Late-stage compounds for treating cancer and HIV are among others for which the company may provide updates.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...